At Sanofi, we are committed to breaking down barriers and supporting healthcare professionals in understanding rare diseases through these challenging times. 

World Meningitis Day is being held on 24 April 2021 to raise awareness of the devastating effects of meningitis and to urge governments from across the world to defeat meningitis by 2030.

At Sanofi, we recognise the importance of working together with patient advocacy groups and to provide partnerships with genuine equity that serve the needs of the patients. Which is why, we have led and published the Future of Advocacy Partnerships Report.

Achieving gender balance is a strategic priority for Sanofi. This report details our April 2020 results and approach we’re taking.

Uncontrolled asthma costs more than just a patients’ physical and mental wellbeing. A new report, authored by UK Think Tank Demos and commissioned by Sanofi, reveals the financial impact on patients and society as a whole. Sanofi remains committed to improving the lives of those living with uncontrolled asthma.

We’re proud to have received our accreditation from the Workplace Wellbeing Charter, recognising our ongoing work in this area.

The COVID-19 pandemic has greatly impacted the global supply chain of nearly every industry. This is a spotlight on our supply chain teams who have been working tirelessly behind the scenes to continue to deliver vital medicines to those who need them, while navigating the challenges of a disruptive world.

There is no one word to describe 2020 – even the Oxford Dictionary team couldn’t pin it down. For us, 2020 was paradoxically unthinkable yet inspiring; heart-wrenching yet heart-warming; divisive yet unifying.

Whilst COVID-19 has done its best to isolate us, cutting us off physically from friends and family, in many ways it has also brought us closer together.

As the unprecedented COVID-19 pandemic continues to spread around the world, Sanofi is at the forefront of multiple initiatives to fight the disease, while also carrying on the daily business of making and delivering medicines for patients.

Why this September may be the most important Blood Cancer Awareness Month of our time.

It is vital that the patient voice remains at the heart of everything we do at Sanofi and that we have meaningful relationships with patient organisations.

Non-melanoma skin cancer (NMSC) is the most common cancer in the UK, yet most people haven’t heard of it, and would struggle to correctly identify its symptoms. Despite the significant physical and emotional distress it can cause, NMSC is still all too often regarded as a minor condition that is easily treatable.

As the unprecedented COVID-19 pandemic continues to spread around the world, Sanofi is at the forefront of multiple initiatives to fight the disease, while also carrying on the daily business of making and delivering medicines for patients.

Achieving gender balance is a strategic priority for Sanofi.

Sanofi celebrates grand opening of new UK headquarters at Thames Valley Park in Reading.

Jessamy Baird, Director of Market Access, shares her thoughts on equality and opportunity at Sanofi UK.

Millennials are distinctively resourceful when using traditional health support and modern technology to meet their health needs.

The UK has world leading universities, a highly-skilled workforce and a life sciences ecosystem that has lead discoveries with a huge impact for people and patients all across the world.  However, for the UK to remain a hub for scientific innovation, it is crucial that all those involved in life sciences work together to maintain momentum and investment in the UK, especially when looking to the landscape beyond Brexit.

An exciting new alliance has been announced between Sanofi and Oxford University Medical Sciences Division.

As the Secretary of State for Health & Social Care has set out, the long-term sustainability of the NHS is reliant on a cultural shift which acknowledges the value of investing in prevention in both principle and practise.